Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20234217 | 0.85 | CES2 (0.40) | CES2SPHK1KDM5AKDM4CGGPS1 | |
| SCHEMBL25769655 | 0.77 | CES2 (0.41) | CES2PLA2G2C | |
| SCHEMBL20133360 | 0.76 | KDM5A (0.33) | CES2SPHK1KDM5AKDM4C | |
| SCHEMBL20206397 | 0.75 | CES2 (0.42) | CES2KDM5AKDM4CS1PR2S1PR1 | |
| SCHEMBL25478324 | 0.74 | CES2 (0.37) | CES2 | |
| SCHEMBL25773461 | 0.72 | CES2 (0.40) | CES2SPHK1PLA2G2C | |
| SCHEMBL24673072 | 0.72 | CES2 (0.39) | CES2PLA2G2C | |
| SCHEMBL26383624 | 0.72 | EPHX2 (0.35) | CES2 | |
| SCHEMBL25706227 | 0.72 | MEN1 (0.34) | CES2 | |
| SCHEMBL22837702 | 0.72 | PIK3CD (0.34) | SPHK1KDM5AKDM4CGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CES2 2381/4885SPHK1 4485/4885KDM5A 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.